POZEN
Inc. a pharmaceutical industry devoted to transforming medication that
transforms lives, introduced data from a Phase 1 study that in fact found that
the investigational compound, PA32540, provides faster safety in comparison to
delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time
and energy to gastric pH. These data have been presented initially at Digestive
Disease Week (DDW) 2012 in San Diego, California with the San Diego Convention
Center on May 19, 2012, at 9:15 a.m. (PT).
"In
this study, the meantime to a gastric pH of higher than 4.0 was quicker along
with PA32540 compared to 40 mg of delayed-release, enteric-coated
omeprazole," said Philip B. Miner, Jr., M.D., President and Medical
Director of a typical Oklahoma Foundation for Digestive Research and co-author
of a typical study. "Moreover, the 24-hour pH control accomplished with
the immediate launch type of omeprazole in PA32540 should be adequate to control
over gastric acidity in patients using chronic aspirin therapy for secondary
cardiovascular control."
No comments:
Post a Comment